NEW YORK – NantKwest on Monday announced promising Phase I safety data for its immunotherapy targeting PD-L1 expressing tumors.
The drug candidate, QUILT-3.064, is being evaluated for safety and primary efficacy in six patients with solid tumors expressing PD-L1, a protein that can play a role in eliciting an immune response against cancer cells.